PharmaCielo Statistics
Total Valuation
PharmaCielo has a market cap or net worth of 9.65 million. The enterprise value is 22.54 million.
| Market Cap | 9.65M |
| Enterprise Value | 22.54M |
Important Dates
The next estimated earnings date is Thursday, March 19, 2026.
| Earnings Date | Mar 19, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 187.98M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +8.73% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 8.33% |
| Owned by Institutions (%) | 0.18% |
| Float | 172.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.92 |
| PB Ratio | -0.90 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.78 |
| EV / Sales | 13.52 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.15
| Current Ratio | 0.15 |
| Quick Ratio | 0.04 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.05 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 37.29% |
| Weighted Average Cost of Capital (WACC) | 9.82% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.87% in the last 52 weeks. The beta is 0.47, so PharmaCielo's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | -7.87% |
| 50-Day Moving Average | 0.05 |
| 200-Day Moving Average | 0.04 |
| Relative Strength Index (RSI) | 46.51 |
| Average Volume (20 Days) | 17,799 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaCielo had revenue of 1.63 million and -4.71 million in losses. Loss per share was -0.03.
| Revenue | 1.63M |
| Gross Profit | -596,091 |
| Operating Income | -4.00M |
| Pretax Income | -4.71M |
| Net Income | -4.71M |
| EBITDA | -3.41M |
| EBIT | -4.00M |
| Loss Per Share | -0.03 |
Balance Sheet
The company has 184,199 in cash and 12.79 million in debt, with a net cash position of -12.61 million.
| Cash & Cash Equivalents | 184,199 |
| Total Debt | 12.79M |
| Net Cash | -12.61M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -10.72M |
| Book Value Per Share | -0.06 |
| Working Capital | -14.38M |
Cash Flow
| Operating Cash Flow | -1.39M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is -36.54%, with operating and profit margins of -245.12% and -288.86%.
| Gross Margin | -36.54% |
| Operating Margin | -245.12% |
| Pretax Margin | -288.86% |
| Profit Margin | -288.86% |
| EBITDA Margin | -208.79% |
| EBIT Margin | -245.12% |
| FCF Margin | n/a |
Dividends & Yields
PharmaCielo does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.73% |
| Shareholder Yield | -8.73% |
| Earnings Yield | -48.82% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PharmaCielo has an Altman Z-Score of -38.78 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -38.78 |
| Piotroski F-Score | 1 |